ESOPRIM S.K 20 MG

Country: Israel

Language: English

Source: Ministry of Health

Buy It Now

Active ingredient:

ESOMEPRAZOLE AS SODIUM

Available from:

K.S.KIM INTERNATIONAL (SK- PHARMA) LTD., ISRAEL

ATC code:

A02BC05

Pharmaceutical form:

HARD CAPSULE

Composition:

ESOMEPRAZOLE AS SODIUM 20 MG

Administration route:

PER OS

Prescription type:

Required

Manufactured by:

TOWA PHARMACEUTICAL EUROPE, S.L., SPAIN

Therapeutic area:

ESOMEPRAZOLE

Therapeutic indications:

Esoprim S.K. 20 mg indicated in adults for:Gastroesophageal Reflux Disease (GERD)- treatment of erosive reflux esophagitis - long-term management of patients with healed esophagitis to prevent relapse - symptomatic treatment of gastroesophageal reflux disease. In combination with appropriate antibacterial therapeutic regimens for the eradication of Helicobacter pylori and- healing of Helicobacter pylori associated duodenal ulcer and prevention of relapse of peptic ulcers in patients with Helicobacter pylori associated ulcers -Patients requiring continued NSAID therapy Healing of gastric ulcers associated with NSAID therapy. - Prevention of gastric and duodenal ulcers associated with NSAID therapy, in patients at risk. - Prolonged treatment after i.v. induced prevention of rebleeding of peptic ulcers. Esoprim S.K 20 mg is indicated in adolescents from the age of 12 years for: Gastro-esophageal Reflux Disease (GERD) - treatment of erosive reflux esophagitis -long-term management of patients with healed esophagitis to prevent relapse-symptomatic treatment of gastro-esophageal reflux diseaseIn combination with antibiotics in treatment of duodenal ulcer caused by Helicobacter pylori.

Authorization date:

2019-10-07

Patient Information leaflet

                                PATIENT LEAFLET IN ACCORDANCE WITH THE PHARMACISTS' REGULATIONS
(PREPARATIONS) - 1986
This medicine is dispensed with a doctor’s prescription only
Inactive ingredients and allergens: see under ‘Important information
about some of this
medicine’s ingredients’ and section 6 ‘Additional
information’.
READ THE ENTIRE LEAFLET CAREFULLY BEFORE YOU START USING THIS
MEDICINE. This leaflet
contains concise information about this medicine. If you have any
further questions, consult
your doctor or pharmacist.
This medicine has been prescribed to treat your illness. Do not pass
it on to others. It may harm
them, even if it seems to you that their illness is similar to yours.
1.
WHAT IS THIS MEDICINE INTENDED FOR?
IN ADULTS, ESOPRIM S.K. 20 MG AND ESOPRIM S.K. 40 MG ARE INTENDED FOR:
Treatment of heartburn with or without inflammation of the gullet
caused by reflux of gastric
acid. Esoprim S.K. reduces the production of acid and helps heal the
gullet by reducing pain
and inflammation.
Treatment of ulcers in the upper part of the gut or stomach caused by
_Helicobacter pylori_
bacteria. Esoprim S.K., in combination with suitable antibiotics,
treats the infection, allows the
ulcer to heal, and prevents its recurrence.
Treatment of gastric ulcer caused by use of non-steroidal
anti-inflammatory drugs (NSAIDs)
such as arthritis (rheumatism) medicines.
Prevention of the formation of gastric ulcers, if you might possibly
develop them as a result
of taking non-steroidal anti-inflammatory drugs (NSAIDs), such as
arthritis (rheumatism)
medicines.
Prolonged treatment with Esoprim S.K. capsules to prevent recurrent
bleeding of a gastric
or duodenal ulcer, after initial treatment with intravenous
Esomeprazole.
In adolescents over the age of 12, Esoprim S.K. 20 mg is intended for:
Treatment of heartburn (with or without inflammation of the gullet)
caused by reflux of
gastric acid. Esoprim S.K. reduces the production of acid and helps
heal the gullet by
reducing pain and inflammation.
Treatment of ulcers in the upper part of the 
                                
                                Read the complete document
                                
                            

Documents in other languages

Patient Information leaflet Patient Information leaflet Arabic 16-08-2020
Patient Information leaflet Patient Information leaflet Hebrew 20-09-2022

Search alerts related to this product